# Basilea Pharmaceutica clinical trials: 60 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 60 trials with Basilea Pharmaceutica as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Basilea Pharmaceutica: 60 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/basilea-pharmaceutica

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 60
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 60, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07916181 | A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis | Basilea Pharmaceutica | Phase 1 | Recruiting | End Stage Renal Disease on Dialysis, Adult | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916181) |
| October 19, 2026 | NCT07881224 | A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects | Basilea Pharmaceutica | Phase 1 | Recruiting | Healthy Adult Participants | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881224) |
| March 30, 2026 | NCT07500181 | A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects | Basilea Pharmaceutica | Phase 1 | Recruiting | Healthy | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07500181) |
| May 8, 2025 | NCT06961708 | A Study of Fosmanogepix in Healthy Adult Chinese Subjects | Basilea Pharmaceutica | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961708) |
| April 13, 2025 | NCT06925321 | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. | Basilea Pharmaceutica | Phase 3 | Recruiting | Invasive Mold Infections | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925321) |
| February 5, 2025 | NCT06808646 | A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin | Basilea Pharmaceutica | Phase 1 | Completed | Drug-drug Interaction Study | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06808646) |
| December 13, 2024 | NCT06733675 | Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination | Basilea Pharmaceutica | Phase 1 | Recruiting | Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06733675) |
| October 30, 2024 | NCT06665555 | Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years) | Basilea Pharmaceutica | Phase 1 | Completed | Pharmacokinetics, Healthy Volunteers | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06665555) |
| May 29, 2024 | NCT06433128 | Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections | Basilea Pharmaceutica | Not applicable | Available | Invasive Fungal Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06433128) |
| May 12, 2023 | NCT05856227 | Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age | Basilea Pharmaceutica | Phase 3 | Completed | Neonatal Sepsis | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05856227) |
| October 17, 2022 | NCT05582187 | A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. | Basilea Pharmaceutica | Phase 1 | Completed | Hepatic Impairment | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05582187) |
| September 6, 2022 | NCT05527834 | Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants | Basilea Pharmaceutica | Phase 1 | Completed | Pharmacokinetics | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05527834) |
| August 8, 2022 | NCT05491733 | A Bioequivalence Study of APX001 High-load and Low-load Tablets | Basilea Pharmaceutica | Phase 1 | Completed | Invasive Fungal Infections | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05491733) |
| August 4, 2022 | NCT05488678 | Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function | Basilea Pharmaceutica | Phase 1 | Completed | Pharmacokinetics | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05488678) |
| June 16, 2022 | NCT05421858 | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. | Basilea Pharmaceutica | Phase 3 | Recruiting | Candidemia, Candidiasis, Invasive | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05421858) |
| May 7, 2021 | NCT04877379 | VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers | Basilea Pharmaceutica | Phase 1 | Completed | Healthy Subjects | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04877379) |
| March 18, 2021 | NCT04804059 | A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of \[14C\]-APX001 in Healthy Males | Basilea Pharmaceutica | Phase 1 | Completed | Fungal Infection | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04804059) |
| October 27, 2020 | NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma | Basilea Pharmaceutica | Phase 1/2 | Terminated | Gastric Adenocarcinoma | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04604132) |
| March 19, 2020 | NCT04314206 | VNRX-5024 Safety and PK in Healthy Adult Volunteers | Basilea Pharmaceutica | Phase 1 | Completed | Healthy Subjects | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04314206) |
| January 28, 2020 | NCT04243863 | VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers | Basilea Pharmaceutica | Phase 1 | Completed | Healthy Volunteers | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04243863) |
| January 27, 2020 | NCT04240886 | Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds | Basilea Pharmaceutica | Phase 2 | Terminated | Invasive Fungal Infections | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04240886) |
| November 18, 2019 | NCT04166669 | A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001 | Basilea Pharmaceutica | Phase 1 | Completed | Fungal Infection | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04166669) |
| November 1, 2019 | NCT04148287 | An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris | Basilea Pharmaceutica | Phase 2 | Completed | Candidemia, Invasive Candidiases, Candida Infection | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04148287) |
| September 23, 2019 | NCT04098692 | Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects | Basilea Pharmaceutica | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04098692) |
| September 12, 2019 | NCT04087876 | Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations | Basilea Pharmaceutica | Not applicable | No longer available | Intrahepatic Cholangiocarcinoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04087876) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 30 |
| Phase 1/2 | 6 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 16 |
| Not applicable | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 45 |
| Terminated | 6 |
| Recruiting | 6 |
| Available | 1 |
| Withdrawn | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Mycoses | 8 |
| Staphylococcal Skin Infections | 6 |
| Streptococcal Infections | 4 |
| Candidemia | 3 |
| Invasive Fungal Infections | 3 |
| Torulopsis | 3 |
| Neoplasms | 3 |
| Pneumonia | 3 |
| Pneumonia, Ventilator-Associated | 3 |
| Cholangiocarcinoma | 3 |
| Liver Neoplasms | 3 |
| Biliary Tract Neoplasms | 3 |
| Hand Dermatoses | 3 |
| Candidiasis, Invasive | 2 |
| Glioblastoma | 2 |
| Staphylococcal Infections | 2 |
| Bacteremia | 2 |
| Sepsis | 2 |
| Healthcare-Associated Pneumonia | 2 |
| Skin Diseases, Infectious | 2 |
| Skin Diseases, Bacterial | 2 |
| Bile Duct Neoplasms | 2 |
| Cellulitis | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Community-Acquired Pneumonia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Fast food restaurants in the United States](https://specstream.ai/data/businesses/fast-food-restaurants/united-states)
- [Cleaning companies in the United States](https://specstream.ai/data/businesses/cleaning-companies/united-states)
- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
- [Thai restaurants in the United States](https://specstream.ai/data/businesses/thai-restaurants/united-states)
- [Process servers in the United States](https://specstream.ai/data/businesses/process-servers/united-states)
